Southeastern Research Center

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Idiopathic pulmonary fibrosis15 trials
• COPD7 trials
• Bronchiectasis3 trials
• Asthma2 trials
• Cystic fibrosis2 trials
• High blood pressure1 trial
• Pulmonary arterial hypertension1 trial
• Rheumatoid arthritis1 trial
• Systemic sclerosis (scleroderma)1 trial

Phase

• Phase 216 trials
• Phase 35 trials
• Phase 12 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed10 trials
• Active, not recruiting7 trials
• Recruiting7 trials
• Enrolling by invitation1 trial
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Avalyn Pharma Inc.2 trials
• Boehringer Ingelheim2 trials
• Hoffmann-La Roche2 trials
• Uniquity One (UNI)2 trials
• United Therapeutics2 trials
• and 17 more

Running trials

• Recruiting

  Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD

  NCT07816835· Phase 4· COPD Foundation· Source

  Contact: Benjamin Bregman, MD

• Recruiting

  Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

  NCT07671911· Phase 3· Trevi Therapeutics· Source

  Contact: Paula Buckley

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

  NCT06911632· Tempus AI· Source

  Contact: Lauren Miller

• Active, not recruiting

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· Phase 2· Calluna Pharma AS· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Avalyn Pharma Inc.· Source

  Contact: Jason Thomason

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Vicore Pharma AB· Source

• Recruiting

  A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

  NCT06559150· Phase 2· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Source

  Contact: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway Toll Free Number

• Active, not recruiting

  A Study to Evaluate Solrikitug in Participants With COPD (ZION)

  NCT06496620· Phase 2· Uniquity One (UNI)· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

  NCT05975983· Phase 2· InSilico Medicine Hong Kong Limited· Source

  Contact: Monique Duncan

• Active, not recruiting

  A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

  NCT07116889· Phase 1· Generate Biomedicines· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· United Therapeutics· Source

• Active, not recruiting

  LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321420· Phase 2· PureTech· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Idiopathic pulmonary fibrosis4 recruiting
• COPD2 recruiting
• Bronchiectasis1 recruiting
• Cystic fibrosis1 recruiting
• High blood pressure1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

  NCT07344558· Phase 1· Mannkind Corporation· Source

• Completed

  A Study to Evaluate Solriktug in Adult Participants With Asthma

  NCT06496607· Phase 2· Uniquity One (UNI)· Source

• Completed

  Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

  NCT06331624· Phase 2· GRI Bio Operations, Inc.· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Withdrawn

  A Study to Investigate Leramistat in Patients With IPF

  NCT05951296· Phase 2· Modern Biosciences Ltd· Source

• Completed

  A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device

  NCT05670587· Boehringer Ingelheim· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

  NCT05495243· Phase 2· Renovion, Inc.· Source

• Completed

  A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

  NCT05238675· Phase 2· Boehringer Ingelheim· Source

• Completed

  Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

  NCT05130970· Phase 2· CSL Behring· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source